← FDA DRUG APPROVALS

FDA ANDA · ANDA211907

ROPIVACAINE HYDROCHLORIDE

Sponsor: HIKMA

APPLICATION
ANDA211907
TYPE
ANDA
ORIGINAL APPROVAL
2024-08-15
LATEST ACTION
2024-08-15
ROUTE
EPIDURAL, INFILTRATION, PERINEURAL, INJECTION
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

ROPIVACAINE HYDROCHLORIDEPrescription
ROPIVACAINE HYDROCHLORIDE 400MG/200ML (2MG/ML) · SOLUTION · INJECTION
ROPIVACAINE HYDROCHLORIDEPrescription
ROPIVACAINE HYDROCHLORIDE 500MG/100ML (5MG/ML) · SOLUTION · INJECTION
ROPIVACAINE HYDROCHLORIDEPrescription
ROPIVACAINE HYDROCHLORIDE 200MG/100ML (2MG/ML) · SOLUTION · INJECTION

Approval history

2024-08-15UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →